Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Pisick, EP; Garrett-Mayer, E; Halabi, S; Mangat, PK; Yang, ES-H; Dib, EG; Burgess, EF; Zakem, MH; Rohatgi, N; Bilen, MA; Warren, SL; Anderson, ST; Rygiel, AL; Schilsky, RL
Volume / Issue
Electronic International Standard Serial Number (EISSN)
International Standard Serial Number (ISSN)